Mp. Hermans
University College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mp. Hermans.
Annales D Endocrinologie | 2011
Philippe Oriot; Mp. Hermans; Philippe L. Selvais; Martin Buysschaert; X de la Tribonnière
The use of retroviral drugs in the treatment of infection by human immunodeficiency virus (HIV) is associated, especially for first generations, with side effects such as lipodystrophy, fatty liver and insulin resistance, which may trigger secondary diabetes or worsen existing diabetes. The use of Glucagon-Like Peptide-1 in obese patients with type 2 diabetes on HIV retroviral as an alternative to insulin therapy is not documented; we report the case of a 47-year-old treated with exenatide when insulin was discontinued. During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25.5% and from 114 to 103 cm. Homeostatic model assessment (HOMA) was used to calculate β-cell secretion which increased from 50 to 78% and insulin sensitivity which increased from 28 to 51%, reflecting a decrease in HbA(1c) by 1.9%. Exenatide may be a new therapeutic option for HIV-infected type 2 diabetes patients undergoing retroviral therapy.
Acta Clinica Belgica | 2004
Mp. Hermans; Martin Buysschaert
Type 2 diabetes is usually characterized by a combination, in variable proportions, of two primary abnormalities affecting insulin secretion and insulin sensitivity respectively. About 80% of subjects with type 2 diabetes mellitus have insulin resistance (IR) and exhibit features of the metabolic syndrome in variable proportion. IR is closely associated with central fat redistribution and excess, abnormal secretion of adipocytokines and recirculation of free acid acids. IR is also characterized by dysregulation of intramyocellular fatty acid metabolism, possibly as a result of inherited metabolic defects affecting e.g. mitochondrial oxidative phosphorylation. IR usually occurs in obese or overweight subjects living in a high-risk environment (sedentarity, high fat and low fi ber intakes, fetal malnutrition, etc...). Lastly, IR is an independent cardiovascular risk factor, and the presence of a metabolic syndrome (MS) phenotype in predisposed individuals, a condition otherwise associated with hypertension and dyslipidemia, often leads to the development of early macroangiopathy. Despite the high prevalence of IR in type 2 diabetes, it is actually the progressive s-cell dysfunction that is the hallmark of type 2 diabetes. This inescapable secretory loss usually leads to progressive worsening of fasting and postprandial glucose levels, as illustrated e.g. in the UKPDS and Belfast studies. Loss of secretory capacity over time is thus the paramount determinant of primary and secondary failures to oral therapy and of requirements for permanent insulin supplementation in later life.
Diabetes & Metabolism | 2010
V. Preumont; Mp. Hermans; Sonia Brichard; Martin Buysschaert
Objectif Nous avons voulu determiner les modifications de la fonction beta-cellulaire (B) et/ou de la sensibilite a l’insuline (S) ainsi que de leur produit combine (BxS), secondaires a l’administration pendant 6 mois d’un traitement par exenatide chez des patients diabetiques de type 2 en echec d’une bitherapie orale.
Diabetes & Metabolism | 2010
Martin Buysschaert; A. Claessens; P. Damoiseaux; Anne-Sophie Dramais; V. Godart; Mp. Hermans; M. Ponchon; S. Proces; Philippe L. Selvais; Jean-Paul Thissen
But Un traitement par exenatide chez des patients diabetiques de type 2 est habituellement associe a une reduction de poids et a une amelioration de l’equilibre glycemique. L’objet de notre etude est d’analyser la relation entre cette perte ponderale et la diminution des taux d’HbA 1c chez des sujets diabetiques de type 2 obeses traites par exenatide pendant 3, 6 et 12 mois. Patients et Methodes 299 patients diabetiques de type 2 obeses (55 % sujets masculins) ont ete recrutes dans 14 hopitaux du Reseau hospitalier. L’exenatide (Byetta) a ete prescrit a la dose de 5 μg deux fois par jour puis, en cas de bonne tolerance, de 10 μg deux fois par jour en association avec une bitherapie par sulfamide et metformine a dose maximale. Nous disposons d’un suivi en terme de poids et d’HbA 1c a 3, 6 et 12 mois apres l’instauration du traitement chez respectivement 230 (âge : 58 ± 11 ans [moyenne ± 1DS], duree du diabete [DD] 10 ± 7 ans) [groupe 1], 160 (âge 59 ± 10; DD : 10 ± 6) [groupe 2] et 94 sujets (âge 59 ± 11 ; DD : 10 ± 6) [groupe 3]. Les correlations entre perte de poids et delta du taux d’HbA 1c ont ete analysees par le coefficient de correlation (r) de Pearson. Resultats Dans les groupes 1, 2 et 3, les poids ont baisse de 97 ± 20 a 94 ± 20 kg (3 mois), 97 ± 21 a 93 ± 21 kg (6 mois) et 98 ± 20 a 94 ± 22 kg (12 mois). Les taux d’HbA 1c dans les trois groupes ont diminue de 9,0 ± 1,3 a 7,8 ± 1,1 % (groupe 1), 9,1 ± 1,5 a 7,7 ± 1,4 % (groupe 2) et de 9,1 ± 1,4 a 7,5 ± 1,2 % (groupe 3). Il existait une correlation significative entre perte de poids et abaissement de l’HbA 1c a 3 mois (r = 0,213 ; p = 0,001), 6 mois (r = 0,213 ; p = 0,001) et 12 mois (r = 0,241 ; p = 0,019). Conclusion L’administration d’exenatide a des patients diabetiques de type 2 obeses est efficace en terme de perte ponderale et de controle glycemique des le 3 e mois de suivi. Cette amelioration est maintenue apres 12 mois. Il existe a tous les temps une relation significative entre la perte de poids et la diminution du taux de l’HbA 1c
Presse Medicale | 1995
Bernard Vandercam; Mp. Hermans; P. Coumans; D. Jacques; Jean-Luc Gala; Jaroslaw Kolanowski
Diabetes & Metabolism | 2011
V. Preumont; Mp. Hermans; Michael Bergman; Martin Buysschaert
/data/revues/12623636/v37i1sS1/S1262363611709259/ | 2011
Philippe Oriot; Mp. Hermans; Martin Buysschaert; Philippe L. Selvais; X de la Tribonnière
Diabetes & Metabolism | 2010
Martin Buysschaert; A. Claessens; P. Damoiseaux; Anne-Sophie Dramais; V. Godart; Mp. Hermans; M. Ponchon; S. Proces; Philippe L. Selvais; Jean-Paul Thissen
Diabetes & Metabolism | 2009
V. Preumont; Jacques Jamart; Mp. Hermans; Martin Buysschaert
Diabetes & Metabolism | 2008
V. Preumont; Mp. Hermans; Martin Buysschaert